[Russian study of efficacy and safety of an angiotensin converting enzyme inhibitor quinapril in patients with hypertension].
Efficacy and safety of an angiotensin converting enzyme inhibitor quinapril were assessed in a 12 week study on 258 patients with 1-2 degree hypertension and various concomitant pathology. The use of quinapril as monotherapy (10-40 mg/day) or in combination with hydrochlorothiazide (12.5 mg/day) was associated with blood pressure (BP) normalization (<140/90 mm Hg) or more then 10% BP lowering in 88% of patients. In the end of the study average blood pressure was 134/84 mm HG. Quinapril was well tolerated. These results allow to recommend the scheme of quinapril use utilized in the study for wide application for the treatment of outpatients with hypertension.
Karpov
Iu A
IuA
Deev
A D
AD
D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000077583:Quinapril; D012426:Russia; D044005:Tetrahydroisoquinolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D044005:Tetrahydroisoquinolines; D000077583:Quinapril